Following receipt of orphan drug designation for its stem cell treatment for the degenerative eye disease retinitis pigmentosa, ReNeuron CEO Michael Hunt explains to Proactiveinvestors, what this means for the company and discusses the positive impact the recent £33m fund raising has had on its share price.

Please click on the link below to access the interview: